Improving Outcomes for Older Adults Undergoing Radiation Therapy
Launched by ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · Jan 31, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, titled "Improving Outcomes for Older Adults Undergoing Radiation Therapy," aims to enhance the care received by individuals aged 65 and older who are undergoing radiation therapy for cancer. The study will look at how well these patients can complete their treatment, any changes in their daily activities, and any side effects they might experience. Participants will be asked to fill out surveys and undergo assessments of their physical and mental abilities at several points during their treatment—before starting radiation, at the end of treatment, and then again at one month, three months, and six months after treatment ends. The results will help doctors make better decisions for future patients.
To be eligible for this study, participants must be at least 65 years old, have a confirmed cancer diagnosis, and be patients receiving radiation therapy at specific Mount Sinai locations. Importantly, there are no specific exclusions, so many older adults with cancer can participate. If you join the trial, you can expect to share your experiences and undergo some assessments to help improve future cancer care for older patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient must be ≥ 65 years
- • Patient must have pathologically confirmed cancer
- • Patient must have the ability to provide informed consent, or have a legally authorized representative (LAR) present to provide informed consent on the participant's behalf
- • Must be radiation oncology patient at Mount Sinai Hospital, Mount Sinai Downtown, or Mount Sinai West.
- Exclusion Criteria:
- • There is no exclusion criteria
About Icahn School Of Medicine At Mount Sinai
The Icahn School of Medicine at Mount Sinai is a premier academic institution located in New York City, renowned for its commitment to advancing medical research, education, and patient care. As a leading sponsor of clinical trials, the institution leverages its state-of-the-art facilities and multidisciplinary expertise to drive innovative research initiatives aimed at improving health outcomes. With a focus on translational medicine, the Icahn School of Medicine collaborates with a diverse network of researchers, clinicians, and industry partners to explore novel therapies and interventions across a wide range of medical disciplines. Its rigorous scientific approach and dedication to ethical standards position it as a trusted leader in the clinical research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
Patients applied
Trial Officials
Kavita Dharmarajan, MD, MSc
Principal Investigator
Icahn School of Medicine at Mount Sinai
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials